Maxim Group Initiates Coverage On Petros Pharma with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has initiated coverage on Petros Pharma (NASDAQ:PTPI) with a Buy rating and set a price target of $4.
December 08, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group analyst Naz Rahman has initiated coverage on Petros Pharma with a Buy rating and a price target of $4.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock's future performance. The price target of $4 indicates a significant upside potential from the current trading price. This can lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100